These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21921847)

  • 1. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Abe T; Ureshino N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2011 Oct; 6(10):1639-48. PubMed ID: 21921847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Kobayashi N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2012 Sep; 7(9):1369-81. PubMed ID: 22858585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
    Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
    J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
    Sorensen BS; Wu L; Wei W; Tsai J; Weber B; Nexo E; Meldgaard P
    Cancer; 2014 Dec; 120(24):3896-901. PubMed ID: 25103305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Umeguchi H; Sueoka-Aragane N; Kobayashi N; Nakamura T; Sato A; Takeda Y; Hayashi S; Sueoka E; Kimura S
    Oncol Rep; 2015 Jan; 33(1):391-6. PubMed ID: 25338771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
    Taniguchi K; Uchida J; Nishino K; Kumagai T; Okuyama T; Okami J; Higashiyama M; Kodama K; Imamura F; Kato K
    Clin Cancer Res; 2011 Dec; 17(24):7808-15. PubMed ID: 21976538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I; Lam DC; Chan K; Chung-Man Ho J; Ip M; Lam WK; Chan TK; Chan V
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
    Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
    J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in Plasma DNA.
    Kimura H; Nishikawa S; Koba H; Yoneda T; Sone T; Kasahara K
    Adv Exp Med Biol; 2016; 924():171-174. PubMed ID: 27753039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.